This trial is completed!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Copd
and you are
over 40
years old
Phase
4
The primary goal of this phase is to monitor the long-term effects.
The treatment is already on the market.
Show me locations

The purpose

The overall objective is to asses the bronchodilator effect of single dose of Formoterol/Budesonide 12/400 mcg fixed combination delivered via Discair® in patients with COPD. Spirometric measurements (FEV1, FVC) will be performed for a period of 12 h at 12 different times: pretreatment (prior to the first dose) and posttreatment (15. min, 30. min, 1 hr, 2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 8 hr, 10 hr ve 12 hr).

Provided treatments

  • Drug: Formoterol/Budesonide 12/400 mcg Discair
Tris trial is registered with FDA with number: NCT03028701. The sponsor of the trial is Neutec Ar-Ge San ve Tic A.Ş and it is looking for 33 volunteers for the current phase.
Official trial title:
Assessment of Bronchodilator Efficacy of Formoterol/Budesonide 12/400 mcg Via Discair in Chronic Obstructive Pulmonary Disease (COPD)